249 related articles for article (PubMed ID: 35873467)
1. Insights Into the Role of Epigenetic Factors Determining the Estrogen Response in Estrogen-Positive Ovarian Cancer and Prospects of Combining Epi-Drugs With Endocrine Therapy.
Sarwar S; Alamro A; Huq F; Alghamdi A
Front Genet; 2022; 13():812077. PubMed ID: 35873467
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogens--tamoxifen, SERMs and beyond.
Dhingra K
Invest New Drugs; 1999; 17(3):285-311. PubMed ID: 10665480
[TBL] [Abstract][Full Text] [Related]
3. The crucial role of epigenetic regulation in breast cancer anti-estrogen resistance: Current findings and future perspectives.
Sukocheva OA; Lukina E; Friedemann M; Menschikowski M; Hagelgans A; Aliev G
Semin Cancer Biol; 2022 Jul; 82():35-59. PubMed ID: 33301860
[TBL] [Abstract][Full Text] [Related]
4. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
7. The prediction of hormonal dependency of mammary cancer.
Block GE; Jensen EV; Polley TZ
Ann Surg; 1975 Sep; 182(3):342-52. PubMed ID: 169754
[TBL] [Abstract][Full Text] [Related]
8. Principles and indications of endocrine treatment of advanced breast cancer.
Mouridsen HT; Palshof T
Recent Results Cancer Res; 1980; 71():112-7. PubMed ID: 7367722
[TBL] [Abstract][Full Text] [Related]
9. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K
Cancer Invest; 2001; 19(6):649-59. PubMed ID: 11486708
[TBL] [Abstract][Full Text] [Related]
11. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.
Madeddu C; Gramignano G; Kotsonis P; Paribello F; Macciò A
Oncol Lett; 2014 Sep; 8(3):1279-1282. PubMed ID: 25120706
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
13. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
14. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
15. Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
King RJ
Contraception; 1991 Jun; 43(6):527-42. PubMed ID: 1651204
[TBL] [Abstract][Full Text] [Related]
16. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
17. A Novel Strategy to Co-target Estrogen Receptor and Nuclear Factor κB Pathways with Hybrid Drugs for Breast Cancer Therapy.
Kastrati I; Siklos MI; Brovkovych SD; Thatcher GRJ; Frasor J
Horm Cancer; 2017 Jun; 8(3):135-142. PubMed ID: 28396978
[TBL] [Abstract][Full Text] [Related]
18. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
19. Endocrine therapy--current benefits and limitations.
Nicholson RI; Johnston SR
Breast Cancer Res Treat; 2005; 93 Suppl 1():S3-10. PubMed ID: 16247594
[TBL] [Abstract][Full Text] [Related]
20. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]